These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 23544424)

  • 1. Hepatitis C replication inhibitors that target the viral NS4B protein.
    Miller JF; Chong PY; Shotwell JB; Catalano JG; Tai VW; Fang J; Banka AL; Roberts CD; Youngman M; Zhang H; Xiong Z; Mathis A; Pouliot JJ; Hamatake RK; Price DJ; Seal JW; Stroup LL; Creech KL; Carballo LH; Todd D; Spaltenstein A; Furst S; Hong Z; Peat AJ
    J Med Chem; 2014 Mar; 57(5):2107-20. PubMed ID: 23544424
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical Characterization and In Vivo Efficacy of GSK8853, a Small-Molecule Inhibitor of the Hepatitis C Virus NS4B Protein.
    Pouliot JJ; Thomson M; Xie M; Horton J; Johnson J; Krull D; Mathis A; Morikawa Y; Parks D; Peterson R; Shimada T; Thomas E; Vamathevan J; Van Horn S; Xiong Z; Hamatake R; Peat AJ
    Antimicrob Agents Chemother; 2015 Oct; 59(10):6539-50. PubMed ID: 26259798
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design and synthesis of spirocyclic compounds as HCV replication inhibitors by targeting viral NS4B protein.
    Tai VW; Garrido D; Price DJ; Maynard A; Pouliot JJ; Xiong Z; Seal JW; Creech KL; Kryn LH; Baughman TM; Peat AJ
    Bioorg Med Chem Lett; 2014 May; 24(10):2288-94. PubMed ID: 24731273
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interaction networks of hepatitis C virus NS4B: implications for antiviral therapy.
    Li S; Yu X; Guo Y; Kong L
    Cell Microbiol; 2012 Jul; 14(7):994-1002. PubMed ID: 22329740
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development and characterization of a replicon-based phenotypic assay for assessing HCV NS4B from clinical isolates.
    Rajyaguru S; Yang H; Martin R; Miller MD; Mo H
    Antiviral Res; 2013 Nov; 100(2):328-36. PubMed ID: 24013002
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Journey around the Medicinal Chemistry of Hepatitis C Virus Inhibitors Targeting NS4B: From Target to Preclinical Drug Candidates.
    Cannalire R; Barreca ML; Manfroni G; Cecchetti V
    J Med Chem; 2016 Jan; 59(1):16-41. PubMed ID: 26241789
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of novel HCV inhibitors: synthesis and biological activity of 6-(indol-2-yl)pyridine-3-sulfonamides targeting hepatitis C virus NS4B.
    Zhang X; Zhang N; Chen G; Turpoff A; Ren H; Takasugi J; Morrill C; Zhu J; Li C; Lennox W; Paget S; Liu Y; Almstead N; Njoroge FG; Gu Z; Komatsu T; Clausen V; Espiritu C; Graci J; Colacino J; Lahser F; Risher N; Weetall M; Nomeir A; Karp GM
    Bioorg Med Chem Lett; 2013 Jul; 23(13):3947-53. PubMed ID: 23683597
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New opportunities in anti-hepatitis C virus drug discovery: targeting NS4B.
    Rai R; Deval J
    Antiviral Res; 2011 May; 90(2):93-101. PubMed ID: 21295075
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of imidazo[2,1-b]thiazole HCV NS4B inhibitors exhibiting synergistic effect with other direct-acting antiviral agents.
    Wang NY; Xu Y; Zuo WQ; Xiao KJ; Liu L; Zeng XX; You XY; Zhang LD; Gao C; Liu ZH; Ye TH; Xia Y; Xiong Y; Song XJ; Lei Q; Peng CT; Tang H; Yang SY; Wei YQ; Yu LT
    J Med Chem; 2015 Mar; 58(6):2764-78. PubMed ID: 25710739
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of the nonstructural protein 4B of hepatitis C virus as a factor that inhibits the antiviral activity of interferon-alpha.
    Xu J; Liu S; Xu Y; Tien P; Gao G
    Virus Res; 2009 Apr; 141(1):55-62. PubMed ID: 19185598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current Drug Discovery for Anti-hepatitis C Virus Targeting NS4B.
    Wang Z; Chen X; Wu C; Xu H; Liu H
    Curr Top Med Chem; 2016; 16(12):1362-71. PubMed ID: 26585935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatitis C virus resistance to protease inhibitors.
    Halfon P; Locarnini S
    J Hepatol; 2011 Jul; 55(1):192-206. PubMed ID: 21284949
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Understanding hepatitis C viral dynamics with direct-acting antiviral agents due to the interplay between intracellular replication and cellular infection dynamics.
    Guedj J; Neumann AU
    J Theor Biol; 2010 Dec; 267(3):330-40. PubMed ID: 20831874
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of a dengue NS4B inhibitor originating from an HCV small molecule library.
    Hernandez-Morales I; Geluykens P; Clynhens M; Strijbos R; Goethals O; Megens S; Verheyen N; Last S; McGowan D; Coesemans E; De Boeck B; Stoops B; Devogelaere B; Pauwels F; Vandyck K; Berke JM; Raboisson P; Simmen K; Lory P; Van Loock M
    Antiviral Res; 2017 Nov; 147():149-158. PubMed ID: 29037976
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 6-(Azaindol-2-yl)pyridine-3-sulfonamides as potent and selective inhibitors targeting hepatitis C virus NS4B.
    Chen G; Ren H; Zhang N; Lennox W; Turpoff A; Paget S; Li C; Almstead N; Njoroge FG; Gu Z; Graci J; Jung SP; Colacino J; Lahser F; Zhao X; Weetall M; Nomeir A; Karp GM
    Bioorg Med Chem Lett; 2015 Feb; 25(4):781-6. PubMed ID: 25613678
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of a novel class of potent HCV NS4B inhibitors: SAR studies on piperazinone derivatives.
    Kakarla R; Liu J; Naduthambi D; Chang W; Mosley RT; Bao D; Steuer HM; Keilman M; Bansal S; Lam AM; Seibel W; Neilson S; Furman PA; Sofia MJ
    J Med Chem; 2014 Mar; 57(5):2136-60. PubMed ID: 24476391
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of a class of HCV inhibitors directed against the nonstructural protein NS4B.
    Cho NJ; Dvory-Sobol H; Lee C; Cho SJ; Bryson P; Masek M; Elazar M; Frank CW; Glenn JS
    Sci Transl Med; 2010 Jan; 2(15):15ra6. PubMed ID: 20371471
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of β-d-2'-deoxy-2'-dichlorouridine nucleotide prodrugs as potent inhibitors of hepatitis C virus replication.
    Pinho P; Kalayanov G; Westerlind H; Rosenquist Å; Wähling H; Sund C; Almeida M; Ayesa S; Tejbrant J; Targett-Adams P; Eneroth A; Lindqvist A
    Bioorg Med Chem Lett; 2017 Aug; 27(15):3468-3471. PubMed ID: 28622881
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Hepatitis C virus-host interaction involved in viral replication: toward the identification of antiviral targets.
    Suzuki T
    Jpn J Infect Dis; 2010 Sep; 63(5):307-11. PubMed ID: 20858994
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus.
    Lamarre D; Anderson PC; Bailey M; Beaulieu P; Bolger G; Bonneau P; Bös M; Cameron DR; Cartier M; Cordingley MG; Faucher AM; Goudreau N; Kawai SH; Kukolj G; Lagacé L; LaPlante SR; Narjes H; Poupart MA; Rancourt J; Sentjens RE; St George R; Simoneau B; Steinmann G; Thibeault D; Tsantrizos YS; Weldon SM; Yong CL; Llinàs-Brunet M
    Nature; 2003 Nov; 426(6963):186-9. PubMed ID: 14578911
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.